Arenavirus and West Nile virus in solid organ transplantation

American Journal of Transplantation

Volumn 13, Issue SUPPL.4, 2013, Pages 361-371

  Singh, N ^a   Levi, M E ^b  

^a Louisiana State University Health Sciences Center at Shreveport   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Arenavirus; donor infection; donor to host transmission; encephalitis; lymphocytic choriomeningitis virus; West Nile virus

Indexed keywords

ALBINTERFERON ALPHA2B; IMMUNOGLOBULIN G; OMR IGG AM; RAPAMYCIN; RIBAVIRIN; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ABORTION; AFRICA; AMERICAN HEMORRHAGIC FEVER; ANTIVIRAL THERAPY; ARENAVIRUS INFECTION; ARGENTINE HEMORRHAGIC FEVER; ARTICLE; ASIA; BLEEDING; BLOOD CLOTTING DISORDER; BOLIVIAN HEMORRHAGIC FEVER; BRAIN DISEASE; CAUSE OF DEATH; CONFUSION; CONGENITAL MALFORMATION; CONJUNCTIVITIS; DIARRHEA; DRUG DOSAGE FORM COMPARISON; DRUG TOLERABILITY; ENCEPHALITIS; EUROPE; EVENING DOSAGE; FACE EDEMA; FEVER; FLACCID PARALYSIS; FLAVIVIRUS INFECTION; FLUID THERAPY; GEOGRAPHIC DISTRIBUTION; GRAFT RECIPIENT; GRAFT REJECTION; HEADACHE; HEMORRHAGIC SHOCK; HEPATITIS; HUMAN; HYPOVOLEMIC SHOCK; IMMUNE RESPONSE; INCUBATION TIME; INFECTION CONTROL; INFECTION RISK; JUNIN VIRUS; LASSA FEVER; LASSA VIRUS; LEUKOPENIA; LISTLESSNESS; LOADING DRUG DOSE; LYMPHADENOPATHY; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MALAISE; MEMORY DISORDER; MENINGITIS; MENINGOENCEPHALITIS; MILD COGNITIVE IMPAIRMENT; MORNING DOSAGE; MOUTH ULCER; MULTIPLE ORGAN FAILURE; MYALGIA; NEUROLOGICAL COMPLICATION; OLIGURIA; ORCHITIS; ORGAN TRANSPLANTATION; PAROTITIS; PHARYNGITIS; PHOTOPHOBIA; PRIORITY JOURNAL; RASH; RISK ASSESSMENT; SEIZURE; THORAX PAIN; THROMBOCYTOPENIA; TREMOR; VENEZUELAN HEMORRHAGIC FEVER; VIREMIA; VIRUS TRANSMISSION; WESTERN HEMISPHERE;

ANTIVIRAL AGENTS; ARENAVIRIDAE INFECTIONS; FLUID THERAPY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ORGAN TRANSPLANTATION; RISK FACTORS; WEST NILE FEVER;

EID: 84874898790     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12128     Document Type: Article

References (86)

1. Childs JE, Glass GE, Ksiazek TG, et al. Human-rodent contact and infection with lymphocytic choriomeningitis and Seoul viruses in an inner-city population. Am J Trop Med Hyg 1991; 44: 117-121.
2. Childs JE, Glass GE, Korch GW, et al. Lymphocytic choriomeningitis virus infection and house mouse (Mus musculus) distribution in urban Baltimore. Am J Trop Med Hyg 1992; 47: 27-34.
3. Foster ES, Signs KA, Marks DR, et al. Lymphocytic choriomeningitis in Michigan. Emerg Infect Dis 2006; 12: 851-853.
4. Ter Meulen J, Lukashevich I, Sidibe K, et al. Hunting of peridomestic rodents and consumption of their meat as possible risk factors for rodent-to-human transmission of Lassa virus in the Republic of Guinea. Am J Trop Med Hyg 1996; 55: 661-666.
5. Baum SG, Lewis AM Jr, Rowe WP, Huebner RJ,. Epidemic nonmeningitic lymphocytic-choriomeningitis-virus infection. An outbreak in a population of laboratory personnel. N Engl J Med 1966; 274: 934-936.
6. Deibel R, Woodall JP, Decher WJ, Schryver GD,. Lymphocytic choriomeningitis virus in man. Serologic evidence of association with pet hamsters. JAMA 1975; 232: 501-504.
7. Jamieson DJ, Kourtis AP, Bell M, Rasmussen SA,. Lymphocytic choriomeningitis virus: An emerging obstetric pathogen ? Am J Obstet Gynecol 2006; 194: 1532-1536.
8. Barton LL, Mets MB, Beauchamp CL,. Lymphocytic choriomeningitis virus: Emerging fetal teratogen. Am J Obstet Gynecol 2002; 187: 1715-1716.
9. Fischer SA, Graham MB, Kuehnert MJ, et al. Transmission of lymphocytic choriomeningitis virus by organ transplantation. N Engl J Med 2006; 354: 2235-2249.
10. de Lamballerie X, Fulhorst CF, Charrel RN,. Prevalence of antibodies to lymphocytic choriomeningitis virus in blood donors in southeastern France. Transfusion 2007; 47: 172-173.
11. Lledó L, Gegúndez MI, Saz JV, Bahamontes N, Beltrán M., Lymphocytic choriomeningitis virus infection in a province of Spain: Analysis of sera from the general population and wild rodents. J Med Virol 2003; 70: 273-275.
12. Riera L, Castillo E, Del Carmen Saavedra M, et al. Serological study of the lymphochoriomeningitis virus (LCMV) in an inner city of Argentina. J Med Virol 2005; 76: 285-289.
13. Park JY, Peters CJ, Rollin PE, Age distribution of lymphocytic choriomeningitis virus serum antibody in Birmingham, Alabama: Evidence of a decreased risk of infection. Am J Trop Med Hyg 1997; 57: 37-41.
14. Bajani MD, Tomori O, Rollin PE, A survey for antibodies to Lassa virus among health workers in Nigeria. Trans R Soc Trop Med Hyg 1997; 91: 379-381.
15. McCormick JB, Webb PA, Krebs JW, Johnson KM, Smith ES,. A prospective study of the epidemiology and ecology of Lassa fever. J Infect Dis 1987; 155: 437-444.
16. Weissenbacher MC, Sabattini MS, Avila MM, et al. Junin virus activity in two rural populations of the Argentine hemorrhagic fever (AHF) endemic area. J Med Virol 1983; 12: 273-280.
17. Price ME, Fisher-Hoch SP, Craven RB, McCormick JB,. A prospective study of maternal and fetal outcome in acute Lassa fever infection during pregnancy. Br Med J 1988; 297: 584-587.
18. Cummins D, McCormick JB, Bennett D, et al. Acute sensorineural deafness in Lassa fever. JAMA 1990; 264: 2093-2096.
19. Adair CV, Gauld RL, Smadel JE,. Aseptic meningitis, a disease of diverse etiology: Clinical and etiologic studies on 854 cases. Ann Intern Med, 1953; 39: 675-704.
20. Palacios G, Druce J, Du L, et al. A new arenavirus in a cluster of fatal transplant-associated diseases. N Engl J Med 2008; 358: 991-998.
21. Brief report: Lymphocytic choriomeningitis virus transmitted through solid organ transplantation-Massachusetts, 2008. MMWR Morb Mortal Wkly Rep, 2008; 57: 799-801.
22. Macneil A, Ströher U, Farnon E, et al. Solid organ transplant-associated lymphocytic choriomeningitis, United States, 2011. Emerg Infect Dis 2012; 18: 1256-1262.
23. Enria DA, Pinheiro F,. Rodent-borne emerging viral zoonosis. Hemorrhagic fevers and hantavirus infections in South America. Infect Dis Clin North Am 2000; 14: 167-184.
24. Maiztegui JI,. Clinical and epidemiological patterns of Argentine haemorrhagic fever. Bull World Health Organ 1975; 52: 567-575.
25. Stinebaugh BJ, Schloeder FX, Johnson KM, Mackenzie RB, Entwisle G, De Alba E., Bolivian hemorrhagic fever. A report of four cases. Am J Med 1966; 40: 217-230.
26. Bausch DG, Rollin PE, Demby AH, et al. Diagnosis and clinical virology of Lassa fever as evaluated by enzyme-linked immunosorbent assay, indirect fluorescent-antibody test, and virus isolation. J Clin Microbiol 2000; 38: 2670-2677.
27. Niklasson BS, Jahrling PB, Peters CJ,. Detection of Lassa virus antigens and Lassa virus-specific immunoglobulins G and M by enzyme-linked immunosorbent assay. J Clin Microbiol 1984; 20: 239-244.
28. McCormick JB, King IJ, Webb PA, et al. Lassa fever. Effective therapy with ribavirin. N Engl J Med 1986; 314: 20-26.
29. Barry M, Russi M, Armstrong L, et al. Brief report: Treatment of a laboratory-acquired Sabia virus infection. N Engl J Med 1995; 333: 294-296.
30. Enria DA, Briggiler AM, Sanchez Z,. Treatment of Argentine hemorrhagic fever. Antiviral Res 2008; 78: 132-139.
31. Kilgore PE, Ksiazek TG, Rollin PE, et al. Treatment of Bolivian hemorrhagic fever with intravenous ribavirin. Clin Infect Dis 1997; 24: 718-722.
32. Huggins JW, Hsiang CM, Cosgriff TM, et al. Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome. J Infect Dis 1991; 164: 1119-1127.
33. Maiztegui JI, Fernandez NJ, de Damilano AJ,. Efficacy of immune plasma in treatment of Argentine haemorrhagic fever and association between treatment and a late neurological syndrome. Lancet 1979; 2: 1216-1217.
34. Garner JS,. Guideline for isolation precautions in hospitals. The Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 1996; 17: 53-80.
35. Borio L, Inglesby T, Peters CJ, et al. Hemorrhagic fever viruses as biological weapons: Medical and public health management. JAMA 2002; 287: 2391-2405.
36. Bausch DG, Hadi CM, Khan SH, Lertora JJ,. Review of the literature and proposed guidelines for the use of oral ribavirin as postexposure prophylaxis for Lassa fever. Clin Infect Dis 2010; 51: 1435-1441.
37. Hadi CM, Goba A, Khan SH, et al. Ribavirin for Lassa fever postexposure prophylaxis. Emerg Infect Dis 2010; 16: 2009-2011.
38. Goicochea MA, Zapata JC, Bryant J, Davis H, Salvato MS, Lukashevich IS,. Evaluation of Lassa virus vaccine immunogenicity in a CBA/J-ML29 mouse model. Vaccine 2012; 30: 1445-1452.
39. Maiztegui JI, McKee KT Jr, Barrera Oro JG, et al. Protective efficacy of a live attenuated vaccine against Argentine hemorrhagic fever. AHF Study Group. J Infect Dis 1998; 177: 277-283.
40. Enria DA, Barrera Oro JG,. Junin virus vaccines. Curr Top Microbiol Immunol 2002; 263: 239-261.
41. Peters CJ, Jahrling PB, Liu CT, Kenyon RH, McKee KT Jr, Barrera Oro JG,. Experimental studies of arenaviral hemorrhagic fevers. Curr Top Microbiol Immunol 1987; 134: 5-68.
42. Araki K, Turner AP, Shaffer VO, et al. mTOR regulates memory CD8 T-cell differentiation. Nature 2009; 460: 108-112.
43. Southam CM, Moore AE,. Induced virus infections in man by the Egypt isolates of West Nile virus. Am J Trop Med Hyg 1954; 3: 19-50.
44. Nash D, Mostashari F, Fine A, et al. The outbreak of West Nile virus infection in the New York City area in 1999. N Engl J Med 2001; 344: 1807.
45. Centers for Disease Control and Prevention. West Nile virus transmission via organ transplantation and blood transfusion-Louisiana, 2008. MMWR 2009; 58: 1263-1267.
46. Dauphin G, Zientara S, Zeller H, Murgue B,. West Nile: Worldwide current situation in animals and humans. Comp Immunol Microbiol Infect Dis. 2004; 27: 343-55.
47. Petersen LR, Marfin AA,. West Nile virus: A primer for the clinician. Ann Intern Med 2002; 137: 173-179.
48. Hayes E, Komar N, Nasci R, Montgomery S, O'Leary D, Campbell G,. Epidemiology and transmission dynamics of West Nile virus disease. Emerg Infect Dis 2005; 11: 1167-1173.
49. West Nile virus surveillance and control: An update for healthcare providers in New York City. New York Department of Health. City Health Information. 2001; 20.
50. Centers for Disease Control and Prevention. Update: Investigations of West Nile virus infections in recipients of organ transplantation and blood transfusion. MMWR 2002; 51: 833-836.
51. Rhee C, Eaton EF, Concepcion W, Blackburn BG,. West Nile virus encephalitis acquired via liver transplantation and clinical response to intravenous immunoglobulin: Case report and review of the literature. Transplant Infect Dis 2011; 13: 312-317.
52. Kumar D, Prasad GV, Zaltzman J, Levy GA, Humar A,. Community-acquired West Nile Virus infection in solid-organ transplant recipients. Transplantation 2004; 77: 399-402.
53. Kleinschmidt-DeMasters BK, Marder BA, Levi ME, et al. Naturally acquired West Nile virus encephalomyelitis in transplant recipients. Ann Neurol 2004; 61: 1210-1220.
54. Mostashari F, Bunning ML, Kitsutani PT, et al. Epidemic West Nile encephalitis, New York, 1999: Results of a household-based seroepidemiological survey. Lancet 2001; 358: 261-264.
55. Levi M, Quan D, Ho J, Kleinschmidt-DeMasters BK, Tyler K, Grazia T,. Impact of rituximab-associated B-cell defects on West Nile virus meningoencephalitis in solid-organ transplant recipients. Clin Transplant 2010; 24: 223-228.
56. Mawhorter S, Sierk A, Staugaitis S, et al. Fatal West Nile virus infection after rituximab/fludarabine-induced remission for non-Hodgkin's lymphoma. Clin Lymphoma Myeloma 2005; 6: 248-250.
57. Diamond M, Shrestha B, Marri A, Mahan D, Engle M,. B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus. J Virol 2003; 77: 2578-2586.
58. Kumar D, Drebot M, Wong S, et al. A seroprevalence study of West Nile virus infection in solid organ transplant recipients. American Journal of Transplantation 2004; 4: 1883-1888.
59. Freifeld AG, Mez J, Schweitzer B, Shafer L, Kalil AC, Sambol AR,. Seroprevalence of West Nile virus infection in solid organ transplant recipients. Transplant Infect Dis 2010; 12: 120-126.
60. Center for Biologics Evaluation and Research, Food and Drug Administration. Guidance for industry: Assessing donor suitability and blood product safety in cases of known or suspected West Nile virus infection. June 2005. Available at: http://www.fda.gov/biologicsbloodvaccines/ guidancecomplianceregulatoryinformation/guidances/blood/ucm074111.htm.
61. Hazell SL,. Serological diagnosis of West Nile virus. http://www2.mlo-online.com/archives/articles/0604/0604coverstory.pdf. 2004.
62. Busch M, Kleinman S, Tobler L, et al. Virus and antibody dynamics in Acute West Nile virus infection. J Infect Dis 2008; 198: 1-10.
63. Roehrig J, Nash D, Maldin B, et al. Persistence of virus-reactive serum immunoglobulin M antibody in confirmed West Nile virus encephalitis cases. Emerg Infect Dis 2003; 9: 376-379.
64. Zak I, Altinok D, Merline J, Chander S, Kish K,. West Nile virus infection. Am J Roentgenol 2005; 184: 957-961.
65. Penn R, Guarner J, Sejvar J, et al. Persistent neuroinvasive West Nile virus infection in an immunocompromised patient. Clin Inf Dis 2006; 42: 680-683.
66. Ben-Nathan D, Lustig S, Tam G, Robinzon S, Segal S, Rager-Zisman B,. Prophylactic and therapeutic efficacy of human intravenous immunoglobulin in treated West Nile virus infection in mice. J Infect Dis 2003; 188: 5-12.
67. Saquib R, Randall H, Chandrakantan A, Spak C,., Barri Y,. West Nile virus encephalitis in a renal transplant recipient: The role of intravenous immunoglobulin. Am J Kidney Dis 2008; e19-e21.
68. Shimoni Z, Niven MJ, Pitlick S, Bulvik S,. Treatment of West Nile virus encephalitis with intravenous immunoglobulin. Emerg Infect Dis 2001; 7: 759.
69. Kreil TR, Eibl MM,. Pre and postexposure protection by passive immunoglobulin, but no enhancement of infection with a flavivirus in a mouse model. J Virol 1997; 71: 2921-2927.
70. Roehrig JT, Staudinger LA, Hunt AR, Mathews JH, Blair CD,. Antibody prophylaxis and therapy for flavivirus encephalitis infections. In: White DJ, Morse DL, eds. West Nile virus detection, surveillance and control. Ann NY Acad Sci 2001; 951: 386-397.
71. Ben-Nathan D, Gershoni-Yahalom O, Samina I, et al. Using high titer West Nile intravenous immunoglobulin from selected Israeli donors for treatment of West Nile virus infection. BMC Infect Dis 2009; 9: 18.
72. Bukowski JF, Welsh RM,. Interferon enhances the susceptibiltiy of virus-infected fibroblasts to cytotoxic T cells. J Exp Med. 1985; 161: 257-262.
73. Planitzer C, Modrol J, Kreil T,. West Nile virus neutralization by US plasma-derived immunoglobulin products. J Infect Dis 2007; 196: 435-440.
74. Jackson AC,. Therapy of West Nile virus infection. Can Neurol Sci 2004; 31: 131-134.
75. Brassard DL, Grace MJ, Bordens RW,. Interferon-alpha as an immunotherapeutic protein. J Leukoc Biol 2002; 71: 565-581.
76. Anderson JF, Rahal JJ,. Efficacy of interferon alpha-2b and ribavirin against West Nile virus in vitro. Emerg Infect Dis 2002; 8: 107-108.
77. Kalil AC, Devetten M, Singh S, et al. Use of interferon-alpha in patients with West Nile encephalitis: Report of two cases. Clin Infect Dis 2005; 40: 764-766.
78. Sayao A-L, Patry D, Suchowersky O, et al. Calgary experience with West Nile virus Neurological syndrome during the late summer of 2003. Can J Neurol Sci 2004; 31: 194-203.
79. Busch M, Caglioti S, Robertson E, et al. Screening the blood supply for West Nile virus RNA by nucleic acid amplification testing. N Engl J Med 2005; 353: 460-467.
80. Brubaker S, Rigney P,. West Nile Virus workshop: Scientific considerations for tissue donors. Cell Tissue Bank; published online 02 December 2011.
81. Zhang W, Wu J, Li Y, Njoo H,. Rapid and accurate in vitro assays for detection West Nile virus in blood and tissues. Transfusion Med Rev 2009; 23: 146-154.
82. http://www.cdc.gov/ncidod/dvbid/westnile/resources/wnv- transplant%20brochure6-12-07.pdf.
83. Morelli MC, Sambri V, Grazi GL, et al. Absence of neuroinvasive disease in a liver transplant recipient who acquired West Nile virus (WNV) infection from the organ donor and who received WNV antibodies prophylactically. Clin Infect Dis 2010; 51: e34-e37.
84. Iwamoto M, Jernigan D, Guasch A, et al. Transmission of West Nile virus from an organ donor to four transplant recipients. N Engl J Med 2003; 348: 2196-2203.
85. St. Martin L,. West Nile Virus and organ transplantation: HRSAs approach. 2005, PowerPoint presentation.
86. Centers for Disease Control and Prevention. West Nile virus infections in organ transplant recipients-New York and Pennsylvania, August-September, 2005. MMWR 2005; 54: 1021-1023.